Learn more about Judy and her current work.
Sex and the rhetoric of drugs: faux feminism at the FDA and how it won the day. segal_keynote
For the discussion to follow Judy’s talk, she has provided the following questions for consideration:
1. There has been a shift recently in medicine and in medicine studies from talking about medical humanities to talking about health humanities. What is the significance of the shift and what might it mean for those of us who work on discourses of health and medicine?
2. At professional conferences and in publications in rhetoric/composition/technical-writing/communication journals, we talk mostly to each other about the rhetoric of health and medicine. Whom else should we be talking to—and how might we create the conditions in which we can talk to those people? Who is/are the audience/s for your own work?
3. Where do analysis and commentary end and activism begin? Is academic writing itself a form of (symbolic) action?
4. What, if any, responsibility do we have to make situations better when we believe that they need to be—and what qualifies us to know when a situation needs to be better, and what “better” means in that case?